Agios Pharmaceuticals Inc (AGIO)

46.90
1.70 3.40
NASDAQ : Health Care
Prev Close 48.56
Open 48.77
Day Low/High 46.85 / 49.20
52 Wk Low/High 33.50 / 119.92
Volume 319.94K
Avg Volume 597.30K
Exchange NASDAQ
Shares Outstanding 48.20M
Market Cap 2.37B
EPS -3.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract

Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract

The new enasidenib data -- improved tumor response rate but shorter duration -- were made public on Wednesday night in a research abstract.

4 Health Care Charts Signaling Buys: Pfizer, Amgen Included

4 Health Care Charts Signaling Buys: Pfizer, Amgen Included

Obamacare? Trumpcare? These stocks don't care.

These 4 Healthcare Charts Are Signaling Buys

These 4 Healthcare Charts Are Signaling Buys

Here's a rundown of four technical setups that are showing solid trading potential.

Biotechs Among 5 Stocks Setting Up for Major Breakouts

Biotechs Among 5 Stocks Setting Up for Major Breakouts

Here's how to rake in the profits off some potential big breakouts.

FDA Accepts New Drug Application And Grants Priority Review For Enasidenib In Relapsed Or Refractory AML With An IDH2 Mutation

FDA Accepts New Drug Application And Grants Priority Review For Enasidenib In Relapsed Or Refractory AML With An IDH2 Mutation

Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals (NASDAQ:AGIO) today announced that the U.

Analysts' Actions -- Chipotle, Disney, Brinker, JPMorgan and More

Analysts' Actions -- Chipotle, Disney, Brinker, JPMorgan and More

Here are Tuesday's top research calls, including upgrades for Disney, Continental Resources and Agios Pharmaceuticals, and downgrades for Chipotle, Brinker International and JPMorgan Chase.

Agios Shelves Rare Anemia Disorder Drug Due to Liver Toxicity, Switches to Backup

Agios Shelves Rare Anemia Disorder Drug Due to Liver Toxicity, Switches to Backup

Agios owns the full rights to both drugs in the PKD development program, which makes them particularly important to the company.

Agios Provides Update On PKR Program

Agios Provides Update On PKR Program

Flagship Ventures Evolves Name To Flagship Pioneering

Flagship Ventures Evolves Name To Flagship Pioneering

Announces Innovative $285 Million Follow-on Capital Pool for Special Opportunities

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud Violations By Agios Pharmaceuticals, Inc. And Certain Officers And Directors

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud Violations By Agios Pharmaceuticals, Inc. And Certain Officers And Directors

Levi & Korsinsky, LLP announces that it has commenced an investigation of Agios Pharmaceuticals, Inc.